What If Penicillin Was Never Discovered?

In September 1928, Alexander Fleming, a Scottish bacteriologist working at St Mary's Hospital in London, returned from a family holiday to find that a mold had contaminated one of his petri dishes of Staphylococcus bacteria — and that the bacteria immediately surrounding the mold had been killed. Fleming identified the mold as a Penicillium species and correctly recognized that it was producing some substance with antibacterial properties, which he named penicillin. He published his findings in 1929, but the discovery attracted relatively little attention at the time. Fleming himself struggled to isolate and stabilize the active compound in a form pure and stable enough for practical medical use, and he largely moved on to other research within a few years.

The discovery's transformation into an actual medicine took another decade and a different set of researchers. Howard Florey and Ernst Chain, working at Oxford University in the late 1930s, revisited Fleming's findings and — critically, with funding and urgency supplied by the outbreak of the Second World War — developed methods to produce and purify penicillin at meaningful scale. Early clinical trials in 1941 were dramatic enough to convince British and American authorities to commit significant wartime industrial resources to mass production — output scaled from barely enough to treat a handful of patients in 1941 to trillions of units annually by 1945 — and by the D-Day landings in June 1944, penicillin was available in large enough quantities to treat Allied soldiers' wounded and infected injuries on a substantial scale, a level of infection control no previous army had ever had access to. Fleming, Florey, and Chain jointly received the 1945 Nobel Prize in Physiology or Medicine for the discovery and its development into a usable drug.

There are two distinct points where this discovery could plausibly have been lost or delayed, and both are worth taking seriously. The first is Fleming's original observation itself: it depended on a specific, almost absurdly contingent set of circumstances — an open window allowing airborne mold spores to enter, an uncovered petri dish, several days' absence during a UK summer with unusually cool, mold-favorable weather, and a bacteriologist observant enough to notice and correctly interpret what most colleagues would likely have simply cleaned up and discarded as a ruined, contaminated experiment. Remove any one of those specific conditions, and Fleming very plausibly never notices anything at all.

The second, arguably more consequential point is Florey and Chain's Oxford work a decade later. Fleming's own published findings sat largely unexploited for close to ten years, and it was specifically their initiative — helped enormously by wartime funding priorities that made antibacterial research for treating battlefield wounds a national priority — that turned an interesting laboratory observation into an actual medicine. Absent the pressure and resources of a major war, it's entirely plausible this translation from observation to usable drug takes considerably longer, or falls to a different, less well-resourced research group.

In a world where the discovery is delayed rather than lost entirely — the more historically grounded version of this counterfactual, since the underlying microbiology of antibiotic-producing molds was always going to be discoverable by someone eventually — the most immediate and consequential impact falls on the Second World War itself. Bacterial infection following battlefield wounds was, prior to antibiotics, one of the largest causes of death and permanent injury among wounded soldiers, often exceeding deaths from the original wound itself. Widely cited estimates put wound-infection mortality in the First World War at around 18%; with penicillin available by 1944, Allied doctors got that figure for treated wounds down to a small fraction of that. Without penicillin available by 1944, Allied casualty rates from infected wounds plausibly stay far closer to the First World War baseline, extending recovery times, increasing rates of amputation, and straining battlefield medical resources at exactly the moment — the Normandy campaign and the subsequent push through Europe — when rapid treatment and return of wounded soldiers to either the front or civilian life mattered enormously to the war's logistics.

Beyond the battlefield, the immediate civilian impact through the 1930s and early 1940s is the continuation of a medical reality that's easy to forget was completely normal within living memory: routine bacterial infections — strep throat, infected cuts, childbirth-related infections, pneumonia — remained a leading cause of death, including among otherwise healthy young adults and children, with no reliable treatment beyond the body's own immune response and, at best, imperfect and often toxic earlier treatments like sulfa drugs.

At the level of individual families and communities, the difference is felt as a continuation of something that, in our actual timeline, ended with startling speed within about a decade of penicillin's wartime rollout: death from infections that today are considered minor and easily treated. Childbirth in particular remained considerably more dangerous without antibiotics available to treat postpartum infection, one of the leading causes of maternal death through the early twentieth century. A scraped knee that became infected, a burst appendix, untreated strep throat progressing to rheumatic fever — all of these retained a genuine, non-trivial chance of becoming fatal or permanently disabling, a risk profile for ordinary daily injury and illness that most people living after the 1950s have never had to seriously reckon with.

Hospitals themselves operate under a different calculus without reliable antibiotics: surgery of almost any kind carries meaningfully higher infection risk, meaning surgeons and physicians remain considerably more conservative about which operations are worth attempting at all, and post-surgical mortality from infection — rather than from the surgery itself — remains a significant statistic that hospital administrators and family members alike had to reckon with directly.

Zoomed out to the scale of public health systems and global population trends, the absence or delay of antibiotics is one of the more genuinely consequential 'what ifs' available, because the real-world impact of penicillin and the antibiotic class of drugs that followed it was enormous and well documented: a very substantial share of the twentieth century's dramatic increase in average life expectancy is attributable to antibiotics and other advances in infectious disease control taken together, and bacterial infections that once ranked among the leading causes of death worldwide dropped sharply in prevalence across countries with access to these drugs.

A meaningfully delayed discovery — say, penicillin arriving as a usable medicine in the 1950s rather than the 1940s — plausibly means a full additional decade or more of the pre-antibiotic mortality baseline continuing across the globe, concentrated especially among infants, mothers in childbirth, and anyone suffering a wound or infection that today would be treated with a short, unremarkable course of pills. It would also very plausibly reshape the postwar Baby Boom demographic story, since infant and childhood mortality from bacterial infection was one of the significant factors antibiotics addressed directly and quickly across the countries that gained early access to them.